Notes from March 16th 2007 U.S. Capitol Briefing on Thailand’s Compulsory Licenses

On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading

March 8, 2007 Geneva Q&A Session on Thai White Paper

Knowledge Ecology International: Q&A Session on Thai White Paper (Facts and Evidences on the 10 Burning Issues Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand) Geneva, Switzerland 8 March 2007 Thiru Balasubramaniam On Thursday,… Continue Reading

CPTech Response to 2006 PhRMA “Special 301” Submission for Chile

March 2006

CPTech Response to 2006 PhRMA “Special 301” Submission for Chile

The “Special 301” Report is a report that the office of the U.S. Trade Representative (USTR) submits annually to the House Ways and Means Committee and the Senate Finance Committee on the adequacy and effectiveness of intellectual property rights protection around the world. The report identifies those countries that the USTR consider “deny adequate and effective protection for IPR or deny fair and equitable market access for U.S. persons that rely on intellectual property protection”.

Continue Reading

Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license

Original page: http://www.cptech.org/ip/health/tamiflu/christinelagarde.html Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license To: Christine LAGARDE, Ministre déléguée au Commerce extérieur, France From: Manon Ress and James Love,… Continue Reading